Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Patent
1997-05-14
2000-01-11
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
514299, 514557, 514646, A61K 9127
Patent
active
060132787
ABSTRACT:
A second generation of antineoplaston therapies with markedly improved antineoplastic activity is disclosed. Among others, members of the antineoplaston family include phenylacetate (PN), 3-phenylacetyl-amino-2, 6, piperidinedione (CN), and hydrolysis derivatives of CN: phenylacetylglutamine (PG) and isophenylacetylglutamine (Iso-PG). In part, these increases in antineoplastic activity result from large increases in the transport of antineoplaston compositions into cells. Importantly and unexpectedly these increases in antineoplastic activity also result from the capacity of the drug delivery system to direct antineoplaston compounds intracellular trafficking to intracellular binding sites influencing cell viability and proliferation. Liposomal formulations of antineoplaston compositions increase in vitro antineoplastic activity by a factor of 750 to 1500 as compared to administration of antineoplaston compounds given without liposomal formulations. In addition, these liposomal formulations enhanced cellular uptake of antineoplaston compounds from 30 to more that 80 fold. Liposomal formulations were also found to increase intracellular levels of the antineoplaston CN (3-phenylacetyl-amino-2,6, piperidinedione) by directing CN to intracellular binding sites that influence cell viability and proliferation and block its hydrolysis. Under conditions where free CN has no antineoplastic activity, liposomally formulated CN can produce essentially complete and relatively long-lasting blockade of cell growth. Cell growth was found to be restored as intracellular levels of bound CN decrease to undetectable levels.
REFERENCES:
patent: 4470970 (1984-09-01), Burzynski
patent: 4522803 (1985-06-01), Lenk et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4621055 (1986-11-01), Theuver
patent: 4663167 (1987-05-01), Lopez-Berestein
patent: 4766046 (1988-08-01), Abra et al.
patent: 4971802 (1990-11-01), Tarcsay et al.
patent: 5116622 (1992-05-01), Burzynski
patent: 5194266 (1993-03-01), Abra et al.
patent: 5238947 (1993-08-01), Hendry
patent: 5288499 (1994-02-01), Janoff et al.
patent: 5443839 (1995-08-01), Meybeck
patent: 5811119 (1998-09-01), Mehta
Ranade in J. Clin. Pharm. 29, pp. 685-694, 1989 (Drug delivery system).
Weiner in Drug dev. & Indust. Pharmacy. 15(10) pp. 1523-1554 (1989).
Xiang et al., "Development of a Combined NMR Paramagnetic Ion-Induced Line-Broadening/Dynamic Light Scattering Method for Permeability Measurements Across Lipid Bilayer Membranes, " Journal of Pharmaceutical Sciences84: 1308-1315 (1995).
Burzynski Stanislaw R.
Byra Anna
Waldbillig Robert J.
Burzynski Research Institute
Kishore Gollamudi S.
LandOfFree
Liposomal antineoplaston therapies with markedly improved antine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Liposomal antineoplaston therapies with markedly improved antine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposomal antineoplaston therapies with markedly improved antine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1459997